Nisa Investment Advisors LLC dramatically reduced its stake in Royalty Pharma PLC, selling nearly 22,000 shares in the third quarter. The move represents a 76.6% decrease, leaving Nisa with 6,689 shares of the biopharmaceutical company’s stock, valued at $236,000.